{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:28:48Z","timestamp":1795120128271,"version":"4.10.3"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41401-020-0454-y","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T13:26:49Z","timestamp":1595942809000},"page":"518-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Autophagy-dependent removal of \u03b1-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson\u2019s disease"],"prefix":"10.1038","volume":"42","author":[{"given":"Yu-Lin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"454_CR1","first-page":"21","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:21.","journal-title":"Nat Rev Dis Prim"},{"key":"454_CR2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LML de Lau","year":"2006","unstructured":"de Lau LML, Breteler MMB. Epidemiology of Parkinson\u2019s disease. Lancet Neurol. 2006;5:525\u201335.","journal-title":"Lancet Neurol."},{"key":"454_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature."},{"key":"454_CR4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-014-1343-6","volume":"128","author":"S Holmqvist","year":"2014","unstructured":"Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Bjorklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014;128:805\u201320.","journal-title":"Acta Neuropathol."},{"key":"454_CR5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.2000.740721.x","volume":"74","author":"M Vila","year":"2000","unstructured":"Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J Neurochem. 2000;74:721\u20139.","journal-title":"J Neurochem"},{"key":"454_CR6","doi-asserted-by":"crossref","first-page":"15240","DOI":"10.1074\/jbc.M312497200","volume":"279","author":"SV Kalivendi","year":"2004","unstructured":"Kalivendi SV, Cunningham S, Kotamraju S, Joseph J, Hillard CJ, Kalyanaraman B. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J Biol Chem. 2004;279:15240\u20137.","journal-title":"J Biol Chem"},{"key":"454_CR7","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137.","journal-title":"Science."},{"key":"454_CR8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kr\u00fcger","year":"1998","unstructured":"Kr\u00fcger R, Kuhn W, M\u00fcller T, Woitalla D, Graeber M, K\u00f6sel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18:106\u20138.","journal-title":"Nat Genet"},{"key":"454_CR9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"JJ Zarranz","year":"2004","unstructured":"Zarranz JJ, Alegre J, G\u00f3mez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164\u201373.","journal-title":"Ann Neurol"},{"key":"454_CR10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","volume":"298","author":"P Brundin","year":"2017","unstructured":"Brundin P, Dave KD, Kordower JH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017;298:225\u201335.","journal-title":"Exp Neurol"},{"key":"454_CR11","doi-asserted-by":"crossref","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","volume":"110","author":"M Decressac","year":"2013","unstructured":"Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Bj\u00f6rklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity. Proc Natl Acad Sci USA. 2013;110:E1817\u2013E1826.","journal-title":"Proc Natl Acad Sci USA"},{"key":"454_CR12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.4161\/auto.25044","volume":"9","author":"M Decressac","year":"2013","unstructured":"Decressac M, Bj\u00f6rklund A. TFEB: pathogenic role and therapeutic target in Parkinson disease. Autophagy. 2013;9:1244\u20136.","journal-title":"Autophagy."},{"key":"454_CR13","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","volume":"29","author":"B Spencer","year":"2009","unstructured":"Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson\u2019s and Lewy body diseases. J Neurosci. 2009;29:13578\u201388.","journal-title":"J Neurosci"},{"key":"454_CR14","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","volume":"30","author":"C Malagelada","year":"2010","unstructured":"Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson\u2019s disease. J Neurosci. 2010;30:1166\u201375.","journal-title":"J Neurosci"},{"key":"454_CR15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrn3068","volume":"12","author":"J Bov\u00e9","year":"2011","unstructured":"Bov\u00e9 J, Mart\u00ednez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci. 2011;12:437\u201352.","journal-title":"Nat Rev Neurosci"},{"key":"454_CR16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0076-6879(78)50026-8","volume":"50","author":"BA Macher","year":"1978","unstructured":"Macher BA, Sweeley CC. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol. 1978;50:236\u201351.","journal-title":"Methods Enzymol"},{"key":"454_CR17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuropharm.2010.10.012","volume":"60","author":"ST Lim","year":"2011","unstructured":"Lim ST, Esfahani K, Avdoshina V, Mocchetti I. Exogenous gangliosides increase the release of brain-derived neurotrophic factor. Neuropharmacology. 2011;60:1160\u20137.","journal-title":"Neuropharmacology."},{"key":"454_CR18","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1007\/s11064-011-0494-2","volume":"36","author":"K Furukawa","year":"2011","unstructured":"Furukawa K, Ohmi Y, Ohkawa Y, Tokuda N, Kondo Y, Tajima O, et al. Regulatory mechanisms of nervous systems with glycosphingolipids. Neurochem Res. 2011;36:1578\u201386.","journal-title":"Neurochem Res"},{"key":"454_CR19","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1471-4159.1988.tb03086.x","volume":"51","author":"M Hadjiconstantinou","year":"1988","unstructured":"Hadjiconstantinou M, Neff NH. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J Neurochem. 1988;51:1190\u20136.","journal-title":"J Neurochem"},{"key":"454_CR20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1350379","volume":"256","author":"JS Schneider","year":"1992","unstructured":"Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science. 1992;256:843\u20136.","journal-title":"Science."},{"key":"454_CR21","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1073\/pnas.85.19.7351","volume":"85","author":"M Favaron","year":"1988","unstructured":"Favaron M, Manev H, Alho H, Bertolino M, Ferret B, Guidotti A, et al. Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex. Proc Natl Acad Sci USA. 1988;85:7351\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"454_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0006-8993(86)91503-9","volume":"398","author":"MV Sofroniew","year":"1986","unstructured":"Sofroniew MV, Pearson RC, Cuello AC, Tagari PC, Stephens PH. Parenterally administered GM1 ganglioside prevents retrograde degeneration of cholinergic cells of the rat basal forebrain. Brain Res. 1986;398:393\u20136.","journal-title":"Brain Res."},{"key":"454_CR23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1212\/WNL.45.6.1149","volume":"45","author":"JS Schneider","year":"1995","unstructured":"Schneider JS, Roeltgen DP, Rothblat DS, Chapas-Crilly J, Seraydarian L, Rao J. GM1 ganglioside treatment of Parkinson\u2019s disease: an open pilot study of safety and efficacy. Neurology. 1995;45:1149\u201354.","journal-title":"Neurology."},{"key":"454_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jns.2010.02.009","volume":"292","author":"JS Schneider","year":"2010","unstructured":"Schneider JS, Sendek S, Daskalakis C, Cambi F. GM1 ganglioside in Parkinson\u2019s disease: Results of a five year open study. J Neurol Sci. 2010;292:45\u201351.","journal-title":"J Neurol Sci"},{"key":"454_CR25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jns.2012.10.024","volume":"324","author":"JS Schneider","year":"2013","unstructured":"Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson\u2019s disease patients. J Neurol Sci. 2013;324:140\u20138.","journal-title":"J Neurol Sci"},{"key":"454_CR26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2015.06.028","volume":"356","author":"JS Schneider","year":"2015","unstructured":"Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Bra\u0161i\u0107 JR, Leiby B, et al. GM1 ganglioside in Parkinson\u2019s disease: Pilot study of effects on dopamine transporter binding. J Neurol Sci. 2015;356:118\u201323.","journal-title":"J Neurol Sci"},{"key":"454_CR27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1748-1716.1983.tb07350.x","volume":"119","author":"LF Agnati","year":"1983","unstructured":"Agnati LF, Fuxe K, Calza L, Benfenati F, Cavicchioli L, Toffano G, et al. Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Physiol Scand. 1983;119:347\u201363.","journal-title":"Acta Physiol Scand"},{"key":"454_CR28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0006-8993(89)90373-9","volume":"484","author":"M Hadjiconstantinou","year":"1989","unstructured":"Hadjiconstantinou M, Mariani AP, Neff NH. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study. Brain Res. 1989;484:297\u2013303.","journal-title":"Brain Res."},{"key":"454_CR29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02935630","volume":"3","author":"SD Skaper","year":"1989","unstructured":"Skaper SD, Leon A, Toffano G. Ganglioside function in the development and repair of the nervous system. From basic science to clinical application. Mol Neurobiol. 1989;3:173\u201399.","journal-title":"Mol Neurobiol"},{"key":"454_CR30","volume":"8","author":"J Liu","year":"2017","unstructured":"Liu J, Wang X, Lu YQ, Duan CL, Gao G, Lu LL, et al. Pink1 interacts with alpha-synuclein and abrogates \u03b1-synuclein-induced neurotoxicity by activating autophagy. Cell Death Dis. 2017;8:e3056.","journal-title":"Cell Death Dis"},{"key":"454_CR31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1471-4159.2011.07180.x","volume":"117","author":"M Su","year":"2011","unstructured":"Su M, Shi JJ, Yang YP, Li J, Zhang YL, Chen J, et al. HDAC6 regulates aggresome-autophagy degradation pathway of \u03b1-synuclein in response to MPP+-induced stress. J Neurochem. 2011;117:112\u201320.","journal-title":"J Neurochem"},{"key":"454_CR32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11481-014-9528-2","volume":"9","author":"LL Chen","year":"2014","unstructured":"Chen LL, Song JX, Lu JH, Yuan ZW, Liu LF, Durairajan SSK, et al. Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt\/mTOR pathway. J Neuroimmune Pharmacol. 2014;9:380\u20137.","journal-title":"J Neuroimmune Pharmacol"},{"key":"454_CR33","first-page":"9436106","volume":"2016","author":"JO Bhangale","year":"2016","unstructured":"Bhangale JO, Acharya SR. Anti-Parkinson activity of petroleum ether extract of ficus religiosa (L.) leaves. Adv Pharmacol Sci. 2016;2016:9436106.","journal-title":"Adv Pharmacol Sci"},{"key":"454_CR34","volume":"13","author":"XH Wang","year":"2012","unstructured":"Wang XH, Lu G, Hu X, Tsang KS, Kwong WH, Wu FX, et al. Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson\u2019s disease. BMC Neurosci. 2012;13:142.","journal-title":"BMC Neurosci"},{"key":"454_CR35","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1248\/bpb.b14-00128","volume":"37","author":"GS Feng","year":"2014","unstructured":"Feng GS, Zhang ZJ, Bao QQ, Zhang ZJ, Zhou LB, Jiang J, et al. Protective effect of chinonin in MPTP-induced C57BL\/6 mouse model of Parkinson\u2019s disease. Biol Pharm Bull. 2014;37:1301\u20137.","journal-title":"Biol Pharm Bull"},{"key":"454_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn1100","volume":"4","author":"M Vila","year":"2003","unstructured":"Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:365\u201375.","journal-title":"Nat Rev Neurosci"},{"key":"454_CR37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JPD-2011-11023","volume":"1","author":"GE Meredith","year":"2011","unstructured":"Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson\u2019s disease: an update. J Parkinsons Dis. 2011;1:19\u201333.","journal-title":"J Parkinsons Dis"},{"key":"454_CR38","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1523\/JNEUROSCI.0711-11.2011","volume":"31","author":"JS Kim-Han","year":"2011","unstructured":"Kim-Han JS, Antenor-Dorsey JA, O\u2019Malley KL. The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci. 2011;31:7212\u201321.","journal-title":"J Neurosci"},{"key":"454_CR39","doi-asserted-by":"crossref","first-page":"175909141877743","DOI":"10.1177\/1759091418777438","volume":"10","author":"XS Zeng","year":"2018","unstructured":"Zeng XS, Geng WS, Jia JJ. Neurotoxin-induced animal models of Parkinson disease: pathogenic mechanism and assessment. ASN Neuro. 2018;10:1759091418777438.","journal-title":"ASN Neuro."},{"key":"454_CR40","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1089\/ars.2011.4033","volume":"16","author":"TN Martinez","year":"2012","unstructured":"Martinez TN, Greenamyre JT. Toxin models of mitochondrial dysfunction in Parkinson\u2019s disease. Antioxid Redox Signal. 2012;16:920\u201334.","journal-title":"Antioxid Redox Signal"},{"key":"454_CR41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","volume":"106-107","author":"SR Subramaniam","year":"2013","unstructured":"Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog Neurobiol. 2013;106-107:17\u201332.","journal-title":"Prog Neurobiol."},{"key":"454_CR42","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s11064-017-2266-0","volume":"42","author":"RW Dai","year":"2017","unstructured":"Dai RW, Zhang SJ, Duan WJ, Wei RR, Chen HF, Cai WB, et al. Enhanced autophagy contributes to protective effects of GM1 ganglioside against A\u03b21-42-induced neurotoxicity and cognitive deficits. Neurochem Res. 2017;42:2417\u201326.","journal-title":"Neurochem Res"},{"key":"454_CR43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1476-5381.2009.00563.x","volume":"159","author":"J Hwang","year":"2010","unstructured":"Hwang J, Lee S, Lee JT, Kwon TK, Kim DR, Kim H, et al. Gangliosides induce autophagic cell death in astrocytes. Br J Pharmacol. 2010;159:586\u2013603.","journal-title":"Br J Pharmacol"},{"key":"454_CR44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neuroscience.2016.10.058","volume":"340","author":"R Kasahara","year":"2017","unstructured":"Kasahara R, Yamamoto N, Suzuki K, Sobue K. The \u03c31 receptor regulates accumulation of GM1 ganglioside-enriched autophagosomes in astrocytes. Neuroscience. 2017;340:176\u201387.","journal-title":"Neuroscience."},{"key":"454_CR45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI73939","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125:25\u201332.","journal-title":"J Clin Invest"},{"key":"454_CR46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","volume":"140","author":"N Mizushima","year":"2010","unstructured":"Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140:313\u201326.","journal-title":"Cell."},{"key":"454_CR47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14:38\u201348.","journal-title":"Nat Rev Neurosci"},{"key":"454_CR48","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.1074\/jbc.M900573200","volume":"284","author":"IG Ganley","year":"2009","unstructured":"Ganley IG, Lam DH, Wang JR, Ding XJ, Chen S, Jiang XJ. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem. 2009;284:12297\u2013305.","journal-title":"J Biol Chem"},{"key":"454_CR49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ceb.2009.12.004","volume":"22","author":"N Mizushima","year":"2010","unstructured":"Mizushima N. The role of the Atg1\/ULK1 complex in autophagy regulation. Curr Opin Cell Biol. 2010;22:132\u20139.","journal-title":"Curr Opin Cell Biol"},{"key":"454_CR50","volume":"9","author":"JS Schneider","year":"2019","unstructured":"Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. GM1 ganglioside modifies \u03b1-synuclein toxicity and is neuroprotective in a Rat \u03b1-synuclein model of parkinson\u2019s disease. Sci Rep. 2019;9:8362.","journal-title":"Sci Rep."},{"key":"454_CR51","first-page":"89","volume":"6","author":"WH Oertel","year":"1997","unstructured":"Oertel WH, Quinn NP. Parkinson\u2019s disease: drug therapy. Baillieres Clin Neurol. 1997;6:89\u2013108.","journal-title":"Baillieres Clin Neurol"},{"key":"454_CR52","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351:2498\u2013508.","journal-title":"N Engl J Med"},{"key":"454_CR53","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised. Lancet. 2014;384:1196\u2013205.","journal-title":"Lancet."},{"key":"454_CR54","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 2001;57:1829\u201334.","journal-title":"Neurology."},{"key":"454_CR55","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","volume":"20","author":"JM Brotchie","year":"2005","unstructured":"Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord. 2005;20:919\u201331.","journal-title":"Mov Disord."},{"key":"454_CR56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2002","unstructured":"Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease. Neurol Sci. 2002;23:41\u201343.","journal-title":"Neurol Sci"},{"key":"454_CR57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd2087","volume":"5","author":"AH Schapira","year":"2006","unstructured":"Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, et al. Novel pharmacological targets for the treatment of Parkinson\u2019s disease. Nat Rev Drug Disco. 2006;5:845\u201354.","journal-title":"Nat Rev Drug Disco"},{"key":"454_CR58","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1007\/s12035-015-9173-7","volume":"53","author":"Q He","year":"2016","unstructured":"He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, et al. Treatment with trehalose prevents behavioral and neurochemical deficits produced in an AAV \u03b1-synuclein rat model of Parkinson\u2019s disease. Mol Neurobiol. 2016;53:2258\u201368.","journal-title":"Mol Neurobiol"},{"key":"454_CR59","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1074\/jbc.M609532200","volume":"282","author":"S Sarkar","year":"2007","unstructured":"Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007;282:5641\u201352.","journal-title":"J Biol Chem"},{"key":"454_CR60","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/auto.8.1.18313","volume":"8","author":"JH Lu","year":"2012","unstructured":"Lu JH, Tan JQ, Durairajan SS, Liu LF, Zhang ZH, Ma L, et al. Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy. 2012;8:98\u2013108.","journal-title":"Autophagy."},{"key":"454_CR61","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/mp.2012.115","volume":"18","author":"JW Steele","year":"2013","unstructured":"Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, et al. Latrepirdine stimulates autophagy and reduces accumulation of \u03b1-synuclein in cells and in mouse brain. Mol Psychiatry. 2013;18:882\u20138.","journal-title":"Mol Psychiatry."},{"key":"454_CR62","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"22","author":"ML Hebron","year":"2013","unstructured":"Hebron ML, Lonskaya I, Moussa CEH. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models. Hum Mol Genet. 2013;22:3315\u201328.","journal-title":"Hum Mol Genet"},{"key":"454_CR63","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbrc.2007.12.187","volume":"367","author":"A Takamura","year":"2008","unstructured":"Takamura A, Higaki K, Kajimaki K, Otsuka S, Ninomiya H, Matsuda J, et al. Enhanced autophagy and mitochondrial aberrations in murine G(M1)-gangliosidosis. Biochem Biophys Res Commun. 2008;367:616\u201322.","journal-title":"Biochem Biophys Res Commun"},{"key":"454_CR64","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1089\/ars.2011.4396","volume":"17","author":"EY Chan","year":"2012","unstructured":"Chan EY. Regulation and function of uncoordinated-51 like kinase proteins. Antioxid Redox Signal. 2012;17:775\u20135.","journal-title":"Antioxid Redox Signal"},{"key":"454_CR65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ceb.2016.02.010","volume":"39","author":"MG Lin","year":"2016","unstructured":"Lin MG, Hurley JH. Structure and function of the ULK1 complex in autophagy. Curr Opin Cell Biol. 2016;39:61\u20138.","journal-title":"Curr Opin Cell Biol"},{"key":"454_CR66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4161\/auto.23323","volume":"9","author":"PM Wong","year":"2013","unstructured":"Wong PM, Puente C, Ganley IG, Jiang XJ. The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy. 2013;9:124\u201337.","journal-title":"Autophagy."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0454-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-0454-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:03:40Z","timestamp":1684602220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-0454-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["454"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-0454-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"16 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}